Discovery of natural product-based drugs from bacterial symbionts of insects
Discovery of natural product-based drugs from bacterial symbionts of insects
批准号:
8047487
负责人:
Cameron Robert Currie
金额:
$247.96万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2013-09-30
关键词:
Acquired Immunodeficiency SyndromeActinobacteria classAddressAnabolismAnimalsAnti-Bacterial AgentsAnti-Infective AgentsAntibiotic ResistanceAntibioticsAntifungal AgentsAntimicrobial ResistanceAreaBacteriaBiological AssayBiological FactorsBiologyBiomedical ResearchCellsCessation of lifeChemicalsChemistryCollaborationsCollectionCommunicable DiseasesCommunitiesComparative Genomic AnalysisDNA SequenceDrug resistanceEvolutionFractionationGeneticGenomeGenomicsGoalsHealthHumanIn VitroInfectionInsectaLaboratoriesLeadLinkMedicalMedicineMetabolicMethicillin ResistanceMicrobeModelingMultidrug-Resistant TuberculosisMusMycosesParasitesPharmaceutical PreparationsPharmacologic SubstancePhysiciansProdrugsProductionPublic HealthRecoveryResearchResearch PersonnelSamplingScienceScientistScreening procedureSequence AnalysisSoilSourceStreptomycesTechnologyTherapeuticTouch sensationTranslationsTuberculosisUnited StatesUnited States National Institutes of HealthWorkbasecytotoxicity testdesigndrug discoveryexhaustgenome sequencingglobal healthhigh throughput screeninghigh throughput technologyinnovationinsightmicrobial genomemultidisciplinarynext generationnovelnovel therapeuticspathogensmall moleculesuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We will capitalize on recent advances in next-generation DNA sequencing to link natural products with the genomes of the microbes that produce them, providing insights into the genetic underpinnings of their synthesis and informing on search strategies for their discovery. Focusing on Global Health: Natural products arguably represent the best drug leads to treat infectious diseases, including those that are the most harmful worldwide. Thus, our work has the potential to lead to drugs relevant to global health. The title of the proposal is: Discovery of natural product-based drugs from bacterial symbionts of insects. Natural products serve as critical drugs or drug precursors with broad pharmaceutical application, including serving as the most effective antibiotics. The wide-spread and rapid evolution of antibiotic-resistance in pathogenic microbes makes the discovery of novel therapeutics to treat infectious diseases of urgent importance. Despite this critical need, small molecule discovery has decreased substantially in recent decades and the pipeline of new antibiotics is rapidly diminishing. The broad goals of this project are to discover novel natural products with high therapeutic potential (Aim 1), identify the anti-infective potential of these small molecules as drug leads through in vitro high throughput screening and murine model work (Aim 2), and, through genomic approaches, to gain insights into the metabolic potential of these bacteria for discovery of secondary metabolites (Aim 3). In our work, we will focus on a large and untapped source of new natural products: insect-associated Actinobacteria. These bacteria appear to be selected by their insect host for their ability to make biologically active small molecules and recent work by Drs. Currie (PI) and Clardy (co-I) has discovered 5 new small molecules, indicating that they represent a promising source for the discovery of natural products. The work proposed by our multidisciplinary team holds the promise to impact the field of drug discovery, generate numerous new drug leads with therapeutic potential and, by translation, to impact the treatment of drug-resistant infectious diseases on a global scale.
PUBLIC HEALTH RELEVANCE: Escalating antimicrobial resistance is a major biomedical challenge. We propose discovering novel natural products and evaluating their efficacy as drug leads for treating infectious diseases of significance for US and Global Heath.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pone.0058387
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Klassen JL, Currie CR]
通讯作者:
Currie CR
DOI:
10.1186/1471-2164-13-14
发表时间:
2012-01-10
期刊:
BMC genomics
影响因子:
4.4
作者:
[Klassen JL, Currie CR]
通讯作者:
Currie CR
DOI:
10.1021/ol301043p
发表时间:
2012-06-01
期刊:
ORGANIC LETTERS
影响因子:
5.2
作者:
[Carr, Gavin, Poulsen, Michael, Klassen, Jonathan L., Hou, Yanpeng, Wyche, Thomas P., Bugni, Tim S., Currie, Cameron R., Clardy, Jon]
通讯作者:
Clardy, Jon
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses
-
批准号:10571219
-
项目类别:
-
资助金额:$92.29万
-
财政年份:2019
-
负责人:Cameron Robert Currie
-
依托单位:
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses
-
批准号:10592386
-
项目类别:
-
资助金额:$129.57万
-
财政年份:2019
-
负责人:Cameron Robert Currie
-
依托单位:
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates
-
批准号:8785545
-
项目类别:
-
资助金额:$7.61万
-
财政年份:--
-
负责人:Cameron Robert Currie
-
依托单位:
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates
-
批准号:9120960
-
项目类别:
-
资助金额:$15.19万
-
财政年份:--
-
负责人:Cameron Robert Currie
-
依托单位:
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates
-
批准号:9335725
-
项目类别:
-
资助金额:$14.29万
-
财政年份:--
-
负责人:Cameron Robert Currie
-
依托单位:
Discovering Antimicrobial Drugs from Symbiotic Actinobacteria from Terrestrial
-
批准号:8836957
-
项目类别:
-
资助金额:$50.97万
-
财政年份:--
-
负责人:Cameron Robert Currie
-
依托单位:
Discovering Antimicrobial Drugs from Symbiotic Actinobacteria from Terrestrial
-
批准号:8642727
-
项目类别:
-
资助金额:$50.36万
-
财政年份:--
-
负责人:Cameron Robert Currie
-
依托单位:
In Vitro Core
-
批准号:8836960
-
项目类别:
-
资助金额:$81.04万
-
财政年份:--
-
负责人:Cameron Robert Currie
-
依托单位:
Discovering Antimicrobial Drugs from Symbiotic Actinobacteria from Terrestrial
-
批准号:9235229
-
项目类别:
-
资助金额:$55.19万
-
财政年份:--
-
负责人:Cameron Robert Currie
-
依托单位:
In Vitro Core
-
批准号:9235233
-
项目类别:
-
资助金额:$65.82万
-
财政年份:--
-
负责人:Cameron Robert Currie
-
依托单位: